secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2023-10-23T23:59:59+00:00
Accession:  0001723128-23-000035
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal raises FY 2023 guidance after Q3 prelim: rev $610-620M, adj EBITDA $150-155M
--------------------------------------------------------------------------------

- Net revenue prelim Q3 2023 $610-620M, up ~13% YoY.
- Adjusted EBITDA $150-155M, up ~21% YoY; income before taxes $18-28M, substantially higher YoY.
- Net leverage declined to ~4.6x from 5.3x at Dec 2022 due to higher profitability and debt reduction.
- Full-year 2023 guidance raised; Co-CEOs cite momentum from generics, biosimilars, and AvKARE.
- IPX203 for Parkinson's on track for potential 2024 launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000035/0001723128-23-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000035/amrx-20231023.htm
  HTML page:      https://secwatch.observer/filing/0001723128-23-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer